Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal... Read more
About me
Hugo Albrecht is a senior lecturer at the University of South Australia conducting research and teaching activities within the Academic Unit of Clinical & Health Sciences. After obtaining his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland, he has gained considerable experience in both commercial and academic settings in Europe and the US. He has focused his research efforts in the fields of cancer, immunology and neuroscience. For over 20 years, Hugo has been dedicated to preclinical pharmaceutical development. He has led over 20 major drug discovery projects while working in industry and academia. Hugo’s current focus is on the development of biochemical and cell-based assay systems, and animal models to identify and test pharmacologically active compounds. Of current interest is the discovery of novel kinase inhibitors for cancer treatment. In line with this he is leading the design of functional nanoparticles for targeted delivery of drugs into tumour cells.
About me
Doctorate in Science University Lausanne Switzerland
Master in Science Federal School Zurich (ETHZ)
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2018 |
Open access
27
|
2018 |
Open access
42
31
5
|
2017 |
Open access
64
59
9
|
2016 |
27
25
4
|
2014 |
Open access
71
69
1
|
Year | Output |
---|---|
2024 |
5
|
2024 |
Open access
1
|
2024 |
Open access
|
2024 |
Open access
3
4
|
2024 |
3
3
3
|
2023 |
Open access
3
2
2
|
2022 |
Open access
9
8
23
|
2022 |
Open access
7
7
7
|
2022 |
6
6
2
|
2021 |
Open access
81
81
2
|
2021 |
Open access
18
17
1
|
2021 |
Open access
6
7
|
2021 |
Open access
38
31
|
2020 |
10
13
1
|
2019 |
6
5
|
2019 |
Open access
10
10
3
|
2019 |
Open access
7
7
1
|
2019 |
Open access
27
24
1
|
2019 |
Open access
21
19
1
|
2018 |
Open access
27
|
2018 |
Open access
42
31
5
|
2017 |
Open access
23
21
|
2017 |
14
15
2
|
2017 |
Open access
33
32
|
2017 |
Open access
64
59
9
|
2016 |
20
19
3
|
2016 |
Open access
22
21
3
|
2016 |
Open access
57
54
5
|
2016 |
27
25
4
|
2015 |
Open access
15
15
3
|
2015 |
Open access
27
25
6
|
2015 |
29
26
7
|
2015 |
35
35
3
|
2014 |
Open access
71
69
1
|
2008 |
40
34
|
External engagement & recognition
Organisation | Country |
---|---|
Australian Nuclear Science and Technology Organisation | AUSTRALIA |
Australian Synchrotron | AUSTRALIA |
CSIRO Australia (Commonwealth Scientific Industrial Research organisation) | AUSTRALIA |
James Cook University | AUSTRALIA |
Royal Adelaide Hospital | AUSTRALIA |
Shandong University | CHINA |
South Australian Health and Medical and Research Institute (SAHMRI) | AUSTRALIA |
University of Adelaide | AUSTRALIA |
University of Applied Sciences and Arts Northwestern Switzerland | SWITZERLAND |
University of Applied Sciences Northwestern Switzerland | SWITZERLAND |
University of New South Wales | AUSTRALIA |
University of South Australia | AUSTRALIA |
Yabao Pharmaceutical Group Co., Ltd | CHINA |
Drug discovery, Drug development
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
Thesis title | Student status |
---|---|
111081 - Introducing a new paradigm for specific targeting of ovarian cancer cells with engineered nanoparticles, using G protein-coupled receptors as molecular entry points | Current |
Development of Cyclin Dependent Kinase Inhibitors for Cancer Treatment | Current |
Preclinical evaluation of transcription regulator/ tyrosine kinase inhibitors for the treatment of cancer | Current |
Targeting ovarian cancer with nanoparticle drug carriers using G protein-coupled receptors as molecular entry sites | Current |
Design, synthesis, and evaluation of novel CDK2 inhibitors as potential anticancer agents | Completed |
Development of cyclin dependent kinase 9 inhibitors for the treatment of cancer | Completed |
Development of drug-eluting stents for the localised delivery of 5-fluorouracil targeted towards the treatment of gastrointestinal cancers | Completed |
Development of injectable hydrogels for the delivery of therapeutic agents | Completed |
Development of pH-responsive polymer-homopolypeptide micelles for drug delivery | Completed |
Development of thermoresponsive polysaccharides as tunable delivery systems | Completed |
Identification and characterisation of Mnk inhibitors as potential anti-cancer agents | Completed |
Novel cyclin-dependent kinase 9 inhibitors for the treatment of cancer: identification and preclinical evaluation | Completed |
Pre-clinical development of a CDK inhibitor for the treatment of cancer | Completed |
Pre-clinical Evaluation of FLT3 Inhibitors for Treatment of Acute Myeloid Leukaemia | Completed |
Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer | Completed |
Preclinical evaluation of novel dual CDK2/5 inhibitors as anticancer drug candidates | Completed |
Targeting prostate cancer cells with elastin like peptide based micelles displaying gastrin releasing peptide | Completed |
Teaching an old dog new tricks: a global approach to enhancing the cytotoxicity of drug-loaded, non-responsive micelles using oligoelectrolytes | Completed |